All In Biotech

NDA 021321 · Vantive US Hlthcare

Extraneal

Icodextrin · Intraperitoneal

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Apr 22, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Dec 20, 2002

Approved uses

2

Original approval plus efficacy supplements

Registered trials

31

4 Phase 3, 2 recruiting

FAERS reports

31,086

25,996 serious, 10,082 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 30, 2025.

EXTRANEAL (icodextrin) is indicated for a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of kidney failure in patients requiring long-term kidney replacement therapy. EXTRANEAL is also indicated to improve (compared to 4.25% dextrose) long-dwell ultrafiltration and clearance of creatinine and urea nitrogen in patients with high average or greater transport characteristics, as defined using the peritoneal equilibration test (PET) [see Clinical Pharmacology ( 12 ), Clinical Studies ( 14 )]. • For a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of kidney failure in patients requiring long-term kidney replacement therapy. ( 1 ) • To improve (compared to 4.25% dextrose) long-dwell ultrafiltration and clearance of creatinine and urea nitrogen in patients with high average or greater transport characteristics, as defined using the peritoneal equilibration test (PET). ( 1 )

Mechanism: EXTRANEAL is an isosmotic peritoneal dialysis solution containing glucose polymers (icodextrin) as the primary osmotic agent. Icodextrin functions as a colloid osmotic agent to achieve ultrafiltration during long peritoneal dialysis dwells. Icodextrin acts in the peritoneal cavity by exerting osmotic pressure across small intercellular pores resulting in transcapillary ultrafiltration throughout the dwell. Like other peritoneal dialysis solutions, EXTRANEAL also contains electrolytes to help normalize electrolyte balance and lactate to help normalize acid-base status.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 17, 2004 Supplement 10 · Efficacy · priority review LabelLetter
  • Dec 20, 2002 Original approval · Type 1 - New Molecular Entity NovelOrphanReviewLabelLetter
1 products under this application
  • EXTRANEAL · ICODEXTRIN 7.5GM/100ML · SOLUTION, INTRAPERITONEAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Icodextrin" as an intervention, any sponsor and status, largest first.

All 31 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death6,024
  • peritonitis1,914
  • peritoneal dialysis complication1,499
  • peritonitis bacterial1,496
  • hypotension1,194
  • pneumonia975
  • myocardial infarction971
  • infection809
  • sepsis747
  • fluid overload728
  • fall715
  • abdominal pain680

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200461
200576
200678
2007158
2008364
2009670
20101,121
20111,506
20121,649
20133,026
20144,314
20154,658
20163,141
20172,331
20181,252
20191,230
20201,192
2021738
2022711
2023712
2024773
2025738
2026587

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 114 on PubMed

Sponsor: Vantive US Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.